Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

The High Cost Of Wasting Liquid Medicines — By The Numbers

By Meagan Parrish | October 19, 2017

That extra bit of every eye drop that always rolls down a patient’s cheek says a lot about the problem of waste in the pharmaceutical industry. As it turns out, some of the medicine is supposed to get wiped away, because the bottle releases drops that are too big for the human eye.

It isn’t just eye-drop makers that are gaming consumers. According to a recent report on medical waste published by ProPublica, the problem exists with several liquid medications and costs American consumers an exorbitant amount every year.

Here’s a look at the issue, by the numbers:

7 microliters = The maximum amount of fluid an eye can absorb from a drop.

25-56 microliters = The average size of droppers on the market today.

16 microliters = The size of a “microdrop” developed by researchers in the 1990s (scientists and drug companies have known about this problem). Glaucoma patients in the study were able to receive the amount of medication needed even though the drop is about half the size of what’s on the market now. However, companies failed to act on the findings and sell the medicines with a smaller drop size.

$3.4 billion = The amount made by drug companies on eye drops for glaucoma and dry eyes last year, according to Market Scope.

10 percent = The amount of medicine wasted administering the top 20 liquide cancer drugs in single-use vials, according to a study from last year. When the medicine was packaged in sharable vials, less of it was wasted. But more than 10 years ago, drug companies began switching to single-use vials, citing supply chain concerns. Now, if a patient with a smaller body weight doesn’t need the whole dose, the rest goes in the trash.

$1.8 billion = Wasted per year by companies switching to single-use vials for the top liquid cancer drugs.

Double = The increase in a person’s chances of going bankrupt after being diagnosed with cancer. Spending money on wasted drugs increases the cost borne by patients.

 

Related Articles Read More >

Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE